New drug combo targets brain inflammation in ALS – hope for slower decline
NCT ID NCT07321860
First seen Jan 10, 2026 · Last updated May 23, 2026 · Updated 20 times
Summary
This study tests whether a combination of two drugs (galunisertib and nerandomilast) can slow the progression of ALS in people who have high levels of a protein called GREM2. The drugs aim to reduce harmful inflammation and scarring in the brain and spinal cord. The trial will include 60 adults with ALS and measure changes in biomarkers over 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS - AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.